Clinical next generation sequencing of pediatric-type malignancies in adult patients identifies novel somatic aberrations
Jorge Galvez Silva1, Fernando F. Corrales-Medina2, Ossama M. Maher1,5, Nizar Tannir3, Winston W. Huh1, Michael E. Rytting1 and Vivek Subbiah1,4
1 Division of Pediatrics, The University of Texas MD Anderson Children’s Cancer Hospital, Houston, TX
2 Division of Pediatric Hematology-Oncology, Department of Pediatrics, University of Miami-Miller School of Medicine, Miami, FL
3 Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
4 Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Correspondence:
Vivek Subbiah, email:
Keywords: Next generation sequencing, Somatic Mutation, Solid Tumors
Received: January 30, 2015 Accepted: February 18, 2015 Published: February 20, 2015
Abstract
Pediatric malignancies in adults, in contrast to the same diseases in children are clinically more aggressive, resistant to chemotherapeutics, and carry a higher risk of relapse. Molecular profiling of tumor sample using next generation sequencing (NGS) has recently become clinically available. We report the results of targeted exome sequencing of six adult patients with pediatric-type malignancies : Wilms tumor(n=2), medulloblastoma(n=2), Ewing’s sarcoma( n=1) and desmoplastic small round cell tumor (n=1) with a median age of 28.8 years . Detection of druggable somatic aberrations in tumors is feasible. However, identification of actionable target therapies in these rare adult patients with pediatric-type malignancies is challenging. Continuous efforts to establish a rare disease registry are warranted.
